Item 8.01 Other Events.

On January 15, 2021, Five Prime Therapeutics, Inc. ("FivePrime") issued a press release announcing that results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT clinical trial evaluating bemarituzumab in combination with mFOLFOX6 in patients with previously untreated advanced FGFR2b+, non-HER2+ gastric or gastroesophageal junction cancer (the "FIGHT Trial") were presented in a late-breaking oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Virtual Annual Symposium by Zev Wainberg, M.D, Associate Professor of Medicine at UCLA, Co-director of the Gastrointestinal Oncology Program and Director of Early Phase Clinical Research at the Jonsson Comprehensive Cancer Center, and an investigator in the FIGHT Trial.

FivePrime also posted a slide presentation to its website that includes information regarding the FIGHT Trial results.

A copy of the press release and slide presentation are filed herewith as Exhibits 99.1 and Exhibit 99.2, respectively, and the information contained in each of the press release and the slide presentation is incorporated by reference into this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.




(d)  Exhibits.



Exhibit
  No.       Description

99.1          Press release issued by FivePrime on January 15, 2021

99.2          Slide presentation

104         Cover Page Interactive Data File (the cover page XBRL tags are
            embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses